Champignon Brands Inc. (CSE: SHRM, OTCQB: SHRMF) has refilled its financial statements and management discussion for the periods ending March 31, 2020, following a review by the British Columbia Securities Commission. The restatement reflects significant changes: the net loss for the three-month period increased from $2,774,986 to $16,329,497, and for the six-month period, from $2,916,302 to $16,470,813, both showing an increase of $13,554,511. Additionally, the company must file a new Listing Statement for its shares to resume trading on the Canadian Securities Exchange.
Champignon Brands Inc. (CSE: SHRM) announced on February 17, 2021, that it will restate its consolidated financial statements and MD&A for the periods ended March 31, 2020, due to incorrect accounting for intangible assets from recent acquisitions totaling approximately $12 million. This adjustment classifies these as transaction costs rather than intangible assets. The company also faces existing cease trade orders that require compliance with new filing conditions to resume trading. The anticipated filings include financial statements for the periods ended June 30, 2020, and September 30, 2020.
Champignon Brands Inc. (CSE: SHRM, OTCQB: SHRMF) announces changes to its Board of Directors. Bill Wilkerson retired after serving since May 2020. Dr. Roger McIntyre expressed gratitude for his contributions. Olga M. Cwiek has been appointed to the Board, bringing extensive governance experience from her previous roles, including at Homewood Health Centre. Champignon specializes in ketamine treatments for mental health issues, collaborating closely with subsidiaries like AltMed Capital Corp.
Champignon Brands Inc. (CSE: SHRM, OTCQB: SHRMF) has published an article featuring the Rapid Mood Screener (RMS) for bipolar I disorder, led by CEO Dr. Roger McIntyre. The RMS aims to improve diagnostic accuracy between bipolar disorder and major depressive disorder (MDD), addressing a significant clinical need. The 6-item screener provides guidance to primary care physicians and highlights the urgent need for timely intervention. With a common misdiagnosis rate of 60% for bipolar disorder, this tool may enhance patient outcomes.